FIG 5.

Studies of plasmochin monotherapy versus plasmochin combined with quinine. (A) Complex dosing regimens of 100 mg plasmochin (orange boxes) or 100 mg plasmochin with 1.25 g coformulated quinine (orange and blue boxes), as recommended by the manufacturer, with days of rest (white boxes) or on consecutive days without rest (right), listing therapeutic outcomes among 63 patients thus treated and followed for at least 2 months after the initiation of therapy (based on data from Sinton and Bird [136]). (B) Based on data from Craige et al. (139), the impact of 15 to 63 mg daily plasmochin (for 14 days) on delayed attacks when administered separately or concurrently with quinine (2 g daily for 8 days) in a total of 38 subjects challenged with the Chesson strain of P. vivax and followed for about 1 year. (C) Based on data from Berliner et al. (140), therapeutic outcomes when plasmochin (90 mg daily for 14 days) was administered before or during quinine therapy (2 g daily for 8 days).